Hologic, Inc. (HOLX) Stock Price: $76.01+0.00 (+0.00%)
The total return cagr for Hologic, Inc. (HOLX) stock is 24.08% over the past 12 months. The 3 year average growth rate is -2.83% and the 5 year cagr is 0.84%. Total return includes dividends reinvested.
The closing share price for Hologic, Inc. (HOLX) stock was $76.01 for Tuesday, April 7, 2026, up +0.00% from the previous day.
HOLX Price Chart
HOLX Key Metrics
See All MetricsHOLX Earnings Preview
Next Earnings Date
Apr 30, 2026
EPS Estimate
1.07
Revenue Est.
$1.03B
Last Quarter Results
EPS
$1.04
vs Estimate
$1.10
Revenue
$1.05B
vs Estimate
$1.03B
HOLX Analyst Ratings
Consensus Rating
Based on 9 analysts
Average Price Target
$76.67
+0.9% upside
Low
$76.00
Current
$76.01
High
$78.00
HOLX Analyst Estimates
Earnings Per Share (EPS) Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q4 2026 | N/A | $1.12 | N/A | 3 |
| Q1 2027 | N/A | $1.16 | N/A | 6 |
| Q2 2027 | N/A | $1.22 | N/A | 3 |
| Q3 2027 | N/A | $1.30 | N/A | 6 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | N/A | $4.42 | N/A | 10 |
| FY 2027 | N/A | $4.80 | N/A | 7 |
Revenue Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q4 2026 | N/A | $1.09B | N/A | 3 |
| Q1 2027 | N/A | $1.07B | N/A | 6 |
| Q2 2027 | N/A | $1.10B | N/A | 3 |
| Q3 2027 | N/A | $1.12B | N/A | 6 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | N/A | $4.20B | N/A | 10 |
| FY 2027 | N/A | $4.41B | N/A | 7 |
Source: FMP Analyst Consensus Estimates. Forward P/E calculated using average EPS estimate for the nearest fiscal year.
HOLX Competitors' Key Metrics
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| 1HOLX | $16.97B | $76.01 | +0.00% | +24.08% | +0.84% | +7.99% |
HOLX Charts
Valuation Charts
Performance Charts
CAGR Charts
Financial Statement Charts
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- Capital Expenditure
- Acquisitions
- Share Buybacks
- Stock-Based Compensation
- Total Assets
- Total Equity
- Cash & Equivalents
- Accounts Receivable
- Inventory
- PP&E
- Goodwill
- Accounts Payable
- Retained Earnings
- Total Debt
- Long-Term Debt
- Short-Term Debt
About Hologic, Inc.
Hologic, Inc. is a medical technology company focused on designing, producing, and marketing a diverse range of diagnostic tests, medical imaging systems, and surgical solutions. Its core mission is to enhance women's health through proactive detection and effective treatment, serving patients in the United States, across Europe, the Asia-Pacific region, and various other international markets. The company operates through four distinct business units: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Within its Diagnostics segment, Hologic provides Aptima molecular diagnostic assays for identifying infectious microorganisms, alongside Aptima viral load tests for conditions like HIV, Hepatitis C, and Hepatitis B. It also offers Aptima and Panther Fusion SARS-CoV-2 assays for detecting the virus, the ThinPrep System for cytology applications, and the Rapid Fetal Fibronectin Test to help clinicians assess the likelihood of premature birth. Furthermore, the company supplies various diagnostic tests for Group B Streptococcus. The Breast Health division delivers advanced imaging and analytical solutions, including 2D and 3D digital mammography systems with accompanying reading workstations. This segment also features minimally invasive breast biopsy guidance systems and devices, products for marking and localizing breast biopsy sites, specimen radiology tools, ultrasound solutions, connectivity options, and products supporting breast-conserving surgical procedures. For GYN Surgical needs, Hologic offers the NovaSure Endometrial Ablation System, designed to manage abnormal uterine bleeding, and the MyoSure Hysteroscopic Tissue Removal System for the excision of uterine fibroids, polyps, and other pathologies. Additionally, the Fluent Fluid Management System facilitates liquid distention during diagnostic and operative hysteroscopic interventions. The Skeletal Health segment includes the Horizon DXA, a dual-energy X-ray system, and the Fluoroscan Insight FD mini C-arm, which is utilized for minimally invasive orthopedic surgical procedures. Hologic distributes its comprehensive product portfolio through a combination of its dedicated direct sales and service teams, as well as via independent distributors and sales representatives. Established in 1985, Hologic, Inc. maintains its corporate headquarters in Marlborough, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Paul Malenchini